Overview

Study of CAR T-cell Therapy in Acute Myeloid Leukemia and Multiple Myeloma

Status:
Recruiting
Trial end date:
2023-06-28
Target enrollment:
Participant gender:
Summary
The purpose of this first-in-man Phase I-IIa study is to evaluate the safety and antitumor activity of autologous CD44v6 CAR T-cells in patients with acute myeloid leukemia (AML) and multiple myeloma (MM).
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
AGC Biologics S.p.A.
MolMed S.p.A.
Collaborator:
Horizon 2020 - European Commission
Treatments:
Cyclophosphamide
Fludarabine